查Helicobacter pylori以预防胃癌:一个实用的随机临床试验
Yi-Chia Lee1,2,3,4, Tsung-Hsien Chiang1,4,5, Han-Mo Chiu1,4
1Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei City, Taiwan.
JAMA
|September 30, 2024
概括
用便免疫化学测试 (FIT) 查Helicobacter pylori (H pylori) 在台湾没有降低胃癌发病率或死亡率. 然而,经过调整的分析表明,对胃癌发病率有潜在的益处,因此需要进一步调查.
科学领域:
- 胃肠病学
- 癌症学
- 预防医学
背景情况:
- 查Helicobacter pylori (H pylori) 对胃癌发生率的影响尚不清楚.
- 胃癌是全球重要的健康问题,需要有效的查策略.
研究的目的:
- 评估邀请个人进行便抗原 (HPSA) 测试以及便免疫化学测试 (FIT) 对胃癌发病率和死亡率的影响.
- 评估结合H pylori和结肠癌查方法的有效性.
主要方法:
- 一项实用随机临床试验,涉及台湾50至69岁居民.
- 参与者被随机分配到接受HPSA+FIT或单独FIT的邀请.
- 主要结局包括胃癌发病率和死亡率,随访持续至2020年12月.
主要成果:
- 在初步分析中,与单独使用FIT相比,使用HPSA+FIT并没有显著降低胃癌发病率或死亡率.
- 经过对查参与和随访时间进行调整后的特异性分析表明,HPSA+FIT组的胃癌发病率 (但死亡率) 显著降低.
- 报告的抗生素治疗的副作用通常是轻微的,包括腹痛和腹.
结论:
- 结合H pylori和结肠癌查的邀请没有显示出胃癌发病率或死亡率的显著降低.
- 经过调整后的分析表明,查对减少胃癌发病率有潜在的益处,需要进一步研究.
- 这些发现突显了查干预措施的复杂性和考虑参与偏差的重要性.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
328
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
328
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
94
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
94
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Gastritis III: Clinical Manifestations and Management
172
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
172
Hazard Ratio
91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
91
Gastroesophageal Reflux Disease II: Clinical Features and Management
57
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
57


